Price Target Changed • Jun 19
Price target increased by 8.6% to ₩383,455 Up from ₩353,167, the current price target is an average from 11 analysts. New target price is 39% above last closing price of ₩276,500. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₩15,956 for next year compared to ₩13,428 last year. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩303,000, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩591,978 per share. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩249,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 10% over the past three years. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩336,000, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩338,220 per share. Buy Or Sell Opportunity • Mar 31
Now 22% undervalued Over the last 90 days, the stock has risen 10% to ₩251,000. The fair value is estimated to be ₩320,450, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Reported Earnings • Mar 24
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: ₩13,428 (up from ₩10,980 in FY 2024). Revenue: ₩884.0b (up 14% from FY 2024). Net income: ₩147.3b (up 20% from FY 2024). Profit margin: 17% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩282,000, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩321,212 per share. Buy Or Sell Opportunity • Mar 04
Now 24% undervalued Over the last 90 days, the stock has risen 22% to ₩283,500. The fair value is estimated to be ₩372,404, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.7% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 28% in 2 years. Earnings are forecast to grow by 31% in the next 2 years. Price Target Changed • Feb 18
Price target increased by 8.8% to ₩271,833 Up from ₩249,909, the current price target is an average from 12 analysts. New target price is 10% below last closing price of ₩302,500. Stock is up 159% over the past year. The company is forecast to post earnings per share of ₩13,750 for next year compared to ₩10,980 last year. Buy Or Sell Opportunity • Feb 13
Now 21% undervalued Over the last 90 days, the stock has risen 36% to ₩302,500. The fair value is estimated to be ₩380,776, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.7% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 28% in the next 2 years. Declared Dividend • Feb 12
Dividend increased to ₩2,600 Dividend of ₩2,600 is 24% higher than last year. Ex-date: 27th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.9%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (15% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 9.8% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 30% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Announcement • Feb 12
Hansol Chemical Co., Ltd., Annual General Meeting, Mar 26, 2026 Hansol Chemical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 513, teheran-ro, gangnam-gu, seoul South Korea Announcement • Feb 11
Hansol Chemical Co., Ltd. announces Annual dividend Hansol Chemical Co., Ltd. announced Annual dividend of KRW 2600.0000 per share, ex-date on March 27, 2026 and record date on March 30, 2026. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩248,000, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩376,985 per share. Price Target Changed • Nov 21
Price target increased by 11% to ₩244,273 Up from ₩219,273, the current price target is an average from 11 analysts. New target price is 18% above last closing price of ₩207,000. Stock is up 95% over the past year. The company is forecast to post earnings per share of ₩13,932 for next year compared to ₩10,980 last year. Reported Earnings • Nov 19
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: ₩4,132 (up from ₩2,757 in 3Q 2024). Revenue: ₩230.0b (up 21% from 3Q 2024). Net income: ₩45.3b (up 45% from 3Q 2024). Profit margin: 20% (up from 16% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 3% per year. Price Target Changed • Sep 16
Price target increased by 9.5% to ₩210,182 Up from ₩191,900, the current price target is an average from 11 analysts. New target price is 5.5% above last closing price of ₩199,300. Stock is up 63% over the past year. The company is forecast to post earnings per share of ₩13,458 for next year compared to ₩10,980 last year. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩199,300, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩340,137 per share. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Auditor & Part-Time Non-Executive Directors Jin-won Park was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩157,200, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩234,331 per share. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩100,400, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 54% over the past three years. Reported Earnings • Mar 13
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: ₩10,980 (up from ₩9,684 in FY 2023). Revenue: ₩776.4b (flat on FY 2023). Net income: ₩122.7b (up 17% from FY 2023). Profit margin: 16% (up from 14% in FY 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) exceeded analyst estimates by 1.0%. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩124,000, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 35% over the past three years. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩113,500, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 45% over the past three years. Announcement • Feb 12
Hansol Chemical Co., Ltd., Annual General Meeting, Mar 18, 2025 Hansol Chemical Co., Ltd., Annual General Meeting, Mar 18, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 513, teheran-ro, gangnam-gu, seoul South Korea Price Target Changed • Nov 28
Price target decreased by 7.2% to ₩194,583 Down from ₩209,583, the current price target is an average from 12 analysts. New target price is 91% above last closing price of ₩101,800. Stock is down 49% over the past year. The company is forecast to post earnings per share of ₩10,807 for next year compared to ₩9,684 last year. Price Target Changed • Nov 16
Price target decreased by 10% to ₩211,667 Down from ₩235,417, the current price target is an average from 12 analysts. New target price is 107% above last closing price of ₩102,100. Stock is down 44% over the past year. The company is forecast to post earnings per share of ₩10,802 for next year compared to ₩9,684 last year. Valuation Update With 7 Day Price Move • Nov 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩102,500, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 7x in the Chemicals industry in South Korea. Total loss to shareholders of 67% over the past three years. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩136,600, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 59% over the past three years. New Risk • Sep 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Reported Earnings • Aug 17
Second quarter 2024 earnings released: EPS: ₩3,230 (vs ₩2,664 in 2Q 2023) Second quarter 2024 results: EPS: ₩3,230 (up from ₩2,664 in 2Q 2023). Revenue: ₩199.1b (up 2.3% from 2Q 2023). Net income: ₩36.4b (up 26% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩135,900, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 48% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩2,100 per share at 1.0% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 19% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%). Price Target Changed • Nov 14
Price target decreased by 7.4% to ₩241,250 Down from ₩260,625, the current price target is an average from 8 analysts. New target price is 34% above last closing price of ₩180,400. Stock is down 14% over the past year. The company is forecast to post earnings per share of ₩9,086 for next year compared to ₩14,099 last year. Major Estimate Revision • Aug 17
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩890.8m to ₩819.3m. EPS estimate also fell from ₩11,488 per share to ₩10,131 per share. Net income forecast to shrink 9.5% next year vs 23% growth forecast for Chemicals industry in South Korea . Consensus price target down from ₩282,778 to ₩266,111. Share price fell 5.7% to ₩178,000 over the past week. Major Estimate Revision • May 22
Consensus EPS estimates fall by 18% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩939.1m to ₩896.7m. EPS estimate also fell from ₩15,065 per share to ₩12,396 per share. Net income forecast to shrink 13% next year vs 28% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩289,091. Share price rose 9.9% to ₩227,000 over the past week. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩235,000, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 222% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩370,768 per share. Reported Earnings • Mar 15
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: ₩14,099 (up from ₩13,332 in FY 2021). Revenue: ₩885.5b (up 15% from FY 2021). Net income: ₩155.1b (up 4.6% from FY 2021). Profit margin: 18% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 9.8%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Dec 21
Upcoming dividend of ₩2,100 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 18% share price gain to ₩215,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 131% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩408,419 per share. Reported Earnings • Aug 18
Second quarter 2022 earnings released: EPS: ₩4,130 (vs ₩3,804 in 2Q 2021) Second quarter 2022 results: EPS: ₩4,130 (up from ₩3,804 in 2Q 2021). Revenue: ₩230.7b (up 23% from 2Q 2021). Net income: ₩45.8b (up 8.3% from 2Q 2021). Profit margin: 20% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 15%, compared to a 24% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 16% share price gain to ₩264,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 223% over the past three years. Price Target Changed • Apr 27
Price target decreased to ₩370,000 Down from ₩406,429, the current price target is an average from 11 analysts. New target price is 60% above last closing price of ₩231,500. Stock is down 5.3% over the past year. The company is forecast to post earnings per share of ₩15,806 for next year compared to ₩13,332 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 17
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: ₩13,332 (up from ₩10,508 in FY 2020). Revenue: ₩768.7b (up 24% from FY 2020). Net income: ₩148.3b (up 27% from FY 2020). Profit margin: 19% (in line with FY 2020). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 18%, compared to a 19% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Feb 18
Price target decreased to ₩375,000 Down from ₩406,429, the current price target is an average from 12 analysts. New target price is 72% above last closing price of ₩218,500. Stock is down 9.7% over the past year. The company is forecast to post earnings per share of ₩14,643 for next year compared to ₩10,508 last year. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩213,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 163% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩410,574 per share. Upcoming Dividend • Dec 22
Upcoming dividend of ₩1,800 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 08 April 2022. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.5%). Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS ₩3,836 (vs ₩3,575 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₩196.5b (up 19% from 3Q 2020). Net income: ₩42.7b (up 7.7% from 3Q 2020). Profit margin: 22% (down from 24% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Oct 28
Price target increased to ₩401,429 Up from ₩369,286, the current price target is an average from 14 analysts. New target price is 19% above last closing price of ₩338,500. Stock is up 133% over the past year. The company is forecast to post earnings per share of ₩15,138 for next year compared to ₩10,508 last year. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS ₩3,804 (vs ₩2,666 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₩187.3b (up 26% from 2Q 2020). Net income: ₩42.3b (up 43% from 2Q 2020). Profit margin: 23% (up from 20% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Aug 15
Price target increased to ₩330,357 Up from ₩306,786, the current price target is an average from 14 analysts. New target price is 11% above last closing price of ₩297,000. Stock is up 90% over the past year. Reported Earnings • May 17
First quarter 2021 earnings released: EPS ₩3,705 (vs ₩2,561 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩177.0b (up 21% from 1Q 2020). Net income: ₩41.2b (up 45% from 1Q 2020). Profit margin: 23% (up from 19% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 20
Full year 2020 earnings released: EPS ₩10,508 (vs ₩7,741 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩619.3b (up 14% from FY 2019). Net income: ₩116.5b (up 36% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Feb 24
Price target raised to ₩257,500 Up from ₩232,308, the current price target is an average from 11 analysts. The new target price is 9.6% above the current share price of ₩235,000. As of last close, the stock is up 143% over the past year. Is New 90 Day High Low • Feb 15
New 90-day high: ₩232,500 The company is up 35% from its price of ₩172,500 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩268,202 per share. Price Target Changed • Feb 09
Price target raised to ₩229,231 Up from ₩212,692, the current price target is an average from 12 analysts. The new target price is close to the current share price of ₩225,500. As of last close, the stock is up 100% over the past year. Announcement • Feb 06
Hansol Chemical Co., Ltd., Annual General Meeting, Mar 24, 2021 Hansol Chemical Co., Ltd., Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Jan 22
New 90-day high: ₩200,000 The company is up 33% from its price of ₩150,500 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 39% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩228,663 per share. Is New 90 Day High Low • Dec 17
New 90-day high: ₩174,000 The company is up 16% from its price of ₩150,000 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩285,717 per share.